openPR Logo
Press release

Personalised tumor vaccines keep cancer in check

08-21-2017 02:12 PM CET | Health & Medicine

Press release from: SMi Group

Throughout the last decade, novel cancer therapeutics has seen tremendous developments, through targeting tumor cell-intrinsic pathways, as well as targeting tumor cell-extrinsic factors such as growth factors.

Notable clinical success of checkpoint inhibitors as well as adoptively transferred genetically engineered T cells further demonstrates the critical role of T-cells in cancer control and rejection. However, many patients still do not respond to checkpoint inhibitor therapies. This creates the need for effective means of expanding the T-cells in patients using cancer vaccines, which will be further explored by MSD, Exicure, Genentech and INSERM.

There has been substantial progress made in these fields and It's time to connect these fields to enable the linking of genetic alterations with the type of immune response. SMi's 6th annual Cancer Vaccines conference will host high level cancer geneticists, cancer biologists, experts in cancer antigen, tumor immunologists and vaccinologists, to discuss the immunological basis for therapeutic cancer vaccines and how the current understanding of cancer genomics, antigens and T-cell biology might enable development of next-generation novel therapies for patients with cancer.

With the increasing use of various immunotherapy strategies in the clinic, it is essential for immunomonitoring techniques to be conducted to follow the response of patients to therapy. Such investigations will enable the discovery of neoantigens that may contribute to the efficacy of treatment. The potential cellular players, the use of screening techniques to monitor effects of treatment and an account of an immunotherapy trial will illustrate what is possible in clinical practice.

Running alongside the conference will an exclusive pre-conference workshop held on Tuesday 26th September 2017.

The Biomarkers of immune response workshop is aimed at both clinical and research investigators to give insights into how to develop tools for both developing new therapeutic strategies and how to monitor responses to treatment. This will enable you to design clinical trials and to set up laboratory investigations to evaluate response to immunotherapy.

Workshop hosts:

Rose-Ann Padua, Research Director, INSERM
Antoine Toubert, Head, Alloimmunity, Autoimmunity, Transplantation, INSERM
Eric Tartour, Head, Laboratory of Clinical Immunology, Hopital Europeen George Pompidou
Sharam Kordasti, Senior Lecturer, Kings College London
Zwi Berneman, Professor of Haematology, University of Antwerp

Cancer Vaccines 2017 is proudly sponsored by Northwest Biotherapeutics

6th annual Cancer Vaccines
27th – 28th September 2017
London, UK
www.cancervaccinesevent.com/OPENPR
Contact e-mail: kwilliams@smi-online.co.uk
Contact tel: +44 (0) 207 827 6012
#smicancervac

About SMi Group:
Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk

Kyra Williams
kwilliams@smi-online.co.uk
SMi Group
1 Westminster Bridge Road
London
SE1 7XW

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Personalised tumor vaccines keep cancer in check here

News-ID: 677523 • Views: 402

More Releases from SMi Group

Registration opens for the 6th Annual Defence Logistics Central and Eastern Euro …
SMi Group reports: Registration and the agenda is now available for SMi Group’s Defence Logistics Central and Eastern Europe Conference, taking place virtually next March As the need for armed forces to enhance and maximise their logistical capacity continues to grow, and with the current political climate in Europe, it is now more important than ever for senior military officials to meet and discuss the planning, joint operations and allied interoperability,
The 6th Annual Maritime Reconnaissance and Surveillance Technology Conference Go …
SMi Group reports: The Maritime Reconnaissance and Surveillance Technology Conference, taking place next February will now take place online. In light of on-going developments with COVID-19, SMi Group have decided to move its 6th annual Maritime Reconnaissance & Surveillance Technology conference on the 3rd-4th February 2021, to a fully online, virtual experience. Attendees of the virtual 2021 conference will be able to... • Create a virtual profile • Connect with sponsors, speakers, delegates, and media
Registration is now for the 14th Annual Border Security Conference
SMi Group reports: Registration and the agenda is now available for the Border Security Conference, taking place in Prague next year With COVID-19 spreading across the globe, the security and integrity of a nation’s borders has rarely been more important than now. Amid this disruption, the problems of migration, cross-border criminality, and smart-borders have become even more critical as rogue elements seek to exploit the situation. These issues need to
Netherlands MoD to Provide Updates and Insight into the Tactical Edge Networking …
Mobile Deployable Communications 2021 will be taking place in Lisbon, Portugal on 27th and 28th January. This annual military conference will bring together leading program managers, strategic decision-makers, industry experts and thought leaders from Europe and further afield to explore the latest developments in communications technology and the challenges associated with electronic warfare. Not only this, but the main event will be preceded by a pre-conference workshop on “The Challenge

All 5 Releases


More Releases for INSERM

The DECISION project - European researchers seek to reduce the number of patient …
21 European institutions join forces to tackle end-stage liver disease and liver failure with a systems medicine approach - Despite a vast array of available interventions and medications, more than 1 million people die of chronic liver disease (cirrhosis) per year worldwide, when the disease progresses to decompensated cirrhosis and acute-on-chronic liver failure (ACLF), a state in which the dysfunctional liver induces failure of other organs. - Following an acute decompensation
MHRA, Pfizer, Autolus and Tusk Theraputics Sign Up for Immuno-Oncology Conferenc …
SMi Reports: Industry leaders MHRA, Pfizer, Autolus, Tusk Therapeutics, KCL, Boehringer Ingelheim and more are amongst the latest organisations to register for Immuno-Oncology 2018 (http://www.immuno-oncology-conference.com/openpr) There’s just 2 weeks until SMi’s Immuno-Oncology conference commences in London on the 26th and 27th September. With limited places left, interested attendees are urged to book soon to avoid missing out on joining an international gathering of immuno-therapy experts at this highly-anticipated conference. Recent Confirmed Attendees
Nektar Therapeutics, Senior Vice President of Biology and Preclinical Developmen …
SMi Group has announced that Johnathan Zalevsky, Senior Vice President Biology & Preclinical Development, Nektar Therapeutics will be chairing day two of the 6th annual Cancer Vaccines conference, which will be taking place on September 27th & 28th 2017. Johnathan is an immunologist, responsible for the research portfolio at Nektar. Possessing extensive experience on the understanding of cellular and humoral immunity as it relates to vaccination technology and the purpose
04-30-2014 | Health & Medicine
Affiris
Parkinson's Vaccine – Top Experts Unite in European Consortium
EU support boosts development of therapeutic vaccines against Parkinson's and Multiple System Atrophy. AFFiRiS leads consortium. An international consortium of top European research teams has received significant EU funding for the development of therapeutic vaccines against Parkinson's Disease (PD) and Multiple System Atrophy (MSA). Led by the Austrian biotech company AFFiRiS AG, the consortium will use a novel tandem strategy to advance the development of two therapeutic vaccine candidates in parallel.
SMi Group announce Cell-Based Assays conference, 3rd & 4th October 2011
SMi Group is delighted to announce their Cell-Based Assays conference, which will be held on the 21st and 22ndNovember 2011 in London. Over the years, SMi has built a reputation as the leading producer of events relating to Cell-Based Assays in Europe. Now in its 4th year, the event has continued to evolve in response to the demands of our delegates and the pharmaceutical industry marketplace. The event will consist of
Bright Cluster Manager chosen for TOP500-class HPC Cluster in France
Consortium led by the University of Bordeaux 1 and including leading universities, research institutes in southwest France purchase 3,168-core supercomputer comprising technology from Dell, Intel and Bright Computing San Jose, California — Bright Computing, a leader in cluster management software, announced today that the company has been selected to provide the cluster management solution for a French research consortium’s new supercomputer. The HPC cluster, to be installed by ClusterVision at